Market Overview

Analysts At Chardan See A 'Pattern Of Missed Guidance' For Esperion Therapeutics

Share:

Chardan Capital analyst Gbola Amusa offered commentary on Esperion Therapeutics Inc (NASDAQ: ESPR) Wednesday morning following troubling company news related to the company's bempedoic acid.

Amusa suggested caution in the name is warranted and noted more than a handful of points which should give pause to investors looking to get involved. The most notable came argued "the release continued what to us is a pattern of missed guidance for Esperion."

The Chardan analyst highlighted six other preliminary concerns.

  • "After 2H16, there may be few expected clinical catalysts for years.
  • Bempedoic acid may launch in 2023 in the US, leaving very limited patent life (2025).
  • We believe ESPR continues to overestimate the size of the statin intolerant (SI) market.
  • We see extremely low likelihood ESPR will meet it's guidance on cash use...
  • On the call, Esperion acknowledged FDA may see the standard of care as potentially changing, meaning the clinical programs Esperion designed may become less relevant.
  • We believe it is a major flaw that Esperion does not plan to rechallenge its statin intolerant patients in trials from here," Amusa said.

    Chardan maintained a Neutral rating and $13 price target on shares of Esperion.

Latest Ratings for ESPR

DateFirmActionFromTo
Mar 2019UpgradesUnderweightNeutral
Dec 2018Initiates Coverage OnSell
Oct 2018Initiates Coverage OnBuy

View More Analyst Ratings for ESPR
View the Latest Analyst Ratings

Posted-In: Analyst Color News Analyst Ratings

 

Related Articles (ESPR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
APDUpgrades215.0
DPZReiterates325.0
ORLYMaintains435.0
NOWMaintains245.0
MCOMaintains195.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Will The Brexit Affect Your Retirement Plans?

Benzinga's M&A Chatter for Wednesday June 29, 2016